Charles R. Kummeth, Chief Executive Officer of Bio-Techne Corporation (NasdaqGS:TECH) said,"Advanced Cell Diagnostics had a stellar year in 2017 with over 50% growth in revenue on a stand-alone basis. This fiscal year we looked forward to adding ACD's growth to the corporate organic metrics. Full integration of the ACD is ongoing, and we anticipate it will be competed in the fiscal year 2018. With revenue growth expected to continue over 40%, we believe it could become a company division in the coming year. Are there more ACDs in our future? We hope so. We are still hungry for more acquisitions and we have the balance sheet capacity for them. But it is important that we acquire assets at good prices and that we have the infrastructure in place to integrate them into the growing company."